Page 46 - Recognizing axial spondyloarthritis - Janneke de Winter

CHAPTER THREE
arthritis was 29.7% (CI 22.4-37.4%) in AS and 27.9% (CI 16.0-41.6%) in nr-axSpA , resulting in a pooled prevalence difference of -3.8% (CI -8.8-1.1%) favoring nr- axSpA (Figure 2A). Quantitative heterogeneity was not statistically significant and the level of inconsistency was low (Chi2 = 1.25, P = 0.74, Tau2 = 0.00, I2 = 0%).
Enthesitis
Pooled analysis showed a current enthesitis prevalence of 13.6% (CI 1.8-31.8%) in AS and 19.5% (CI 7.1-35.7%) in nr-axSpA, resulting in a pooled prevalence difference of -4.9% (CI -10.9-1.0%) favoring nr-axSpA. Quantitative heterogeneity was statistically significant and the level of inconsistency was moderate (Chi2 = 11.37, P = 0.02, Tau2 = 0.00, I2 = 65%). The pooled prevalence of a history of enthesitis was 28.8% (CI 2.6-64.8%) in AS and 35.4% (CI 6.1-71.2%) in nr-axSpA, resulting in a pooled prevalence difference of -5.4% (CI -9.7-0.0%) favoring nr- axSpA (Figure 2B). Quantitative heterogeneity was statistically significant and the level of inconsistency was moderate (Chi2 = 12.17, P = 0.03, Tau2 = 0.00, I2 = 34%).
Dactylitis
Pooled analysis showed a current dactylitis prevalence of 5.6% (CI 0.0-16.2%) in AS and 5.2% (CI 0.4-13.7%) in nr-axSpA, resulting in a pooled prevalence difference of -0.5% (CI -2.6-1.6%) favoring nr-axSpA. Quantitative heterogeneity was not statistically significant and the level of inconsistency was moderate (Chi2 = 3.31, P = 0.19, Tau2 = 0.00, I2 = 40%). The pooled prevalence of a history of dactylitis was 6.0% (CI 4.7-7.5%) in AS and 6.0% (CI 1.9-12.0%) in nr-axSpA, resulting in a pooled prevalence difference of -0.9% (CI -6.7-4.8%) favoring nr- axSpA (Figure 2C). Quantitative heterogeneity was statistically significant and the level of inconsistency was moderate (Chi2 = 7.37, P = 0.03, Tau2 = 0.00, I2 = 73%).
Uveitis
Pooled analysis showed a current uveitis prevalence of 5.7% (CI 1.4-12.2%) in AS and 6.1% (CI 2.8-10.5%) in nr-axSpA, resulting in a pooled prevalence difference of -0.3% (CI -2.3-1.8%) favoring nr-axSpA. Quantitative heterogeneity was not statistically significant and the level of inconsistency was low (Chi2 = 3.46, P = 0.48, Tau2 = 0.00, I2 = 0%). The pooled prevalence of a history of uveitis was 23.0% (CI 19.2-27.1%) in AS and 15.9% (CI 11.8-20.4%) in nr-axSpA, resulting in a pooled prevalence difference of 6.2% (CI 2.7-9.6%) favoring AS (Figure 3A). Quantitative heterogeneity was statistically significant and the level of inconsistency was low (Chi2 = 5.94, P = 0.008, Tau2 = 0.00, I2 = 16%).
Psoriasis
Pooled analysis showed a psoriasis prevalence of 10.2% (CI 7.5-13.2%) in AS and 10.9% (CI 9.1-13.0%) in nr-axSpA, resulting in a pooled prevalence difference of -0.7% (CI -2.9-1.6%) favoring nr-axSpA (Figure 3B). Quantitative heterogeneity was not statistically significant and the level of inconsistency was low (Chi2 = 7.01,
44